Collaborator Failure to Continue Development. If Collaborator suspends development of the Test Article without the transfer of its active development efforts, assets, and obligations to a third party within ninety (90) days of discontinuation, Collaborator agrees that ICD may continue developing the Test Article. In that event, the following will apply:
Collaborator Failure to Continue Development. If Collaborator suspends development of the Test Article without the transfer of its active development efforts, assets, and obligations to a third party within […***…] of discontinuation, Collaborator agrees that ICD may continue developing the Test Article. In that event, the following will apply:
Collaborator Failure to Continue Development. If Collaborator suspends development of the Investigational Agent without the transfer of its active development efforts, assets, and obligations to a third party within […***…] days of discontinuation, Collaborator agrees that IC may continue developing the Investigational Agent. In that event, Collaborator agrees to transfer to IC all information necessary to enable IC to contract for the manufacture of the Investigational Agent and, unless abandoned for reasons relating to safety as determined by the data safety monitoring board, to provide the Investigational Agent (and Placebo, if any) in Collaborator’s inventory to IC.
Collaborator Failure to Continue Development. If Collaborator suspends development of the Investigational Agent without the transfer of its active development efforts, assets, and obligations to a third party within ninety (90) days of discontinuation, Collaborator agrees that ICD may continue developing the Investigational Agent. In that event, the following will apply:
Collaborator Failure to Continue Development. If Collaborator suspends development of the Investigational Agent without the transfer of its active development efforts, assets, and obligations to a third party within one hundred eighty (180) days of discontinuation, Collaborator agrees that IC may continue developing the Investigational Agent. In that event, Collaborator agrees to transfer to IC all information necessary to enable IC to contract for the manufacture of the Investigational Agent and, unless abandoned for reasons relating to safety as determined by the data safety monitoring board, to provide the Investigational Agent (and Placebo, if any) in Collaborator’s inventory to IC or arrange for an independent contractor to manufacture and provide Investigational Agent to IC for two years or until the completion of ongoing mutually agreed to Protocols.
Collaborator Failure to Continue Development. If Collaborator suspends all development of the Test Article other than for reasons relating to safety, without the transfer of its active development efforts, assets, and obligations to a third party within one hundred and eighty (180) days of discontinuation, Collaborator agrees that IC may continue developing the Test Article. In that event, the following will apply: Collaborator agrees to transfer to IC all information necessary to enable IC to contract for the manufacture of the Test Article or arrange for an independent contractor to manufacture and provide Test Article to IC for the earlier of two years or until completion of ongoing mutually agreed to Protocols, and, unless abandoned for reasons relating to safety as determined by the data safety monitoring board, to provide the Test Article (and Placebo, if any) in Collaborator’s inventory to IC.
Collaborator Failure to Continue Development. If Collaborator permanently ceases the further development of the Investigational Agent (other than due to safety or) without the license or other transfer of its active development efforts, assets, and obligations to a third party within [*] of such discontinuation, Collaborator agrees that IC may request the right to continue developing the Investigational Agent. In such event, Collaborator agrees (subject to its other contractual obligations) to transfer to IC such information in its possession and control as is necessary to enable IC to contract for the manufacture of the [ * ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. Investigational Agent and, unless discontinued for reasons relating to safety as determined by the data safety monitoring board, to provide the Investigational Agent (and Placebo, if any) in Collaborator’s inventory to IC for the completion of ongoing and approved clinical studies. The foregoing is subject to the following: it is understood that in no event shall Collaborator have any obligation to grant rights or to assist IC, and that Collaborator is under no obligation in any event to assist IC in any manufacture or use of Investigational Agent.
Collaborator Failure to Continue Development. If Collaborator suspends development of the Test Article without the transfer of its active development efforts, assets, and obligations to a third party within ninety (90) days of discontinuation, Collaborator agrees that ICD may continue developing the Test Article. In that event, the following will apply: PHS ECT-CRADA Case Ref. No. _______ MODEL ADOPTED 2005 [ * ] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
Collaborator Failure to Continue Development. 10.6.1 If Collaborator suspends development of the Investigational Agent without the transfer of its active development efforts, assets, and obligations to a third party within one hundred eighty (180) days of discontinuation, Collaborator agrees that NCI may continue developing the Investigational Agent. In that event, Collaborator agrees to transfer to NCI all information necessary to enable NCI to contract for the manufacture of the Investigational Agent and, unless abandoned for reasons relating to safety as determined by the Data Safety Monitoring Board, to provide the Investigational Agent (and Placebo, if any) in Collaborator’s inventory to NCI or arrange for an independent contractor to manufacture and provide Investigational Agent to NCI for two years or until the completion of ongoing mutually agreed to Protocols.
